News

July 7, 2020July 7, 2020

3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients

News

An ongoing observational registry study is evaluating Kiyatec‘s novel technology, in which a patient’s own tumor tissue is cultured in a lab dish and exposed to different therapies as a ... Read more

June 30, 2020June 30, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

News, syndicated

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for marketed ... Read more

June 30, 2020June 30, 2020

Second Surgery May Aid Survival in Recurrent Ovarian Cancer, Study Finds

News

Woman whose ovarian cancer returns more than six months after initial surgery and chemotherapy may benefit from a second surgery, but only if the entire tumor is removed during the procedure, ... Read more

June 25, 2020June 25, 2020

Groups Pledge Funding for Project to Develop Ovarian Cancer Blood Test

News

A team at Griffith University’s Institute for Glycomics in Australia has received $300,000 in funding from The Bourne Foundation, as well as a further funding pledge from Tour de Cure, to advance ... Read more

June 23, 2020June 23, 2020

Protein Biomarkers to Gauge Cancer Response to Chemo Identified

News

Investigators using targeted proteomics — a technique to detect proteins of interest — on samples of ovarian cancer found a wide variety of biomarkers that might help predict which chemotherapies patients are more ... Read more

June 18, 2020June 18, 2020

Mirvetuximab Soravtansine-Avastin Combo Linked to Promising Responses

News

When given alongside Avastin (bevacizumab), mirvetuximab soravtansine leads to promising treatment responses in women with recurrent ovarian cancer — particularly those whose tumors contain high levels of the protein folate ... Read more

June 16, 2020June 16, 2020

DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show

News

A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in women with heavily-treated advanced ovarian cancer, with some responses lasting more than 10 months, updated ... Read more

June 11, 2020June 11, 2020

Zejula-Bevacizumab Combo Delays Progression in Relapsed Ovarian Cancer, Trial Finds

News

A combination of bevacizumab and Zejula (niraparib) is significantly better than Zejula alone at extending the time without disease progression in people with platinum-sensitive relapsed ovarian cancer, findings from a clinical ... Read more

June 9, 2020June 9, 2020

More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows

News

VBL Therapeutic’s investigational therapy VB-111 (ofranergene obadenovec) continues to show promising response rates in women with platinum-resistant ovarian cancer, with more than half of patients enrolled in a Phase 3 ... Read more

June 4, 2020June 4, 2020

Genetic Testing for Breast, Ovarian Cancer Risk Safely Done at Home, Trial Shows

News

Genetic tests to assess the risk of breast and ovarian cancer can be performed remotely in the safety of the patients’ homes, according to data from an early Phase 1 ... Read more